RNS Number : 1519U
Synectics PLC
27 March 2019
 

Synectics plc

("Synectics" or the "Company")

 

Exercise of Share Plan Options and Director/PDMR dealings

 

27 March 2019

 

Synectics (AIM: SNX), a leader in the design, integration, control and management of advanced surveillance technology and networked security systems, announces that on 26 March 2019 options over ordinary shares of 20p each in the Company ("Shares"), which vested under the performance criteria of its Performance Share Plan ("PSP"), were exercised and either held or sold at a price of £2.04 per Share, as follows:

 

Name

Position

Status

PSP options exercised

Shares retained in own name

Shares sold

Paul Webb*

Chief Executive

Executive Director

30,000

15,793

14,207

Stacey Anderson

Managing Director, SSS Management Services

PDMR

4,000

-

4,000

Amanda Larnder*

Financial Controller

PDMR

7,500

4,326

3,174

 

*Paul Webb, Chief Executive, and Amanda Larnder sold sufficient Shares to cover the immediate tax liability on exercise of the options. The balance of 15,793 and 4,326 shares respectively were transferred into their own names.

 

Following these transactions, their total interests in Synectics shares are now as follows:

 

Name

Shares Held

Interest in Shares in Share Schemes

Resultant Total Interest

% of Issued Share Capital

Paul Webb

52,115

246,923

299,038

1.68%

Stacey Anderson

-

12,000

12,000

0.07%

Amanda Larnder

4,326

2,500

6,826

0.04%

 

Full details of the PSP are set out in the Company's Annual Report for the year ended 30 November 2018.

 

For further information, please contact:

 

Synectics plc

Claire Stewart, Company Secretary

Tel: +44(0) 114 255 2509

 

Stockdale Securities

Tom Griffiths / Henry Willcocks

Tel: +44 (0) 20 7601 6100


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHEAPDXAAPNEEF